ONCO-ND1 Platform: Immunological characterization of tumor samples for the identification of markers for response to immunotherapies.
ONCO-ND1 line. As for the ONCO-ND1 line, the use of immune checkpoint inhibitors has highlighted the great potential of such immuno-oncological therapies characterized by positive and long-lasting responses never seen before.